20 (AIDX) Equity Ratio (2024 - 2026)
20 (AIDX) reported Equity Ratio of 0.44 for Q1 2026, up 9566.94% quarter-over-quarter from 0.0 in Q4 2025.
20 (AIDX) Equity Ratio (2024 - 2026) Analysis & Trends
20 has reported Equity Ratio for 3 years, with the latest figure at 0.44 in Q1 2026.
- For the quarter ending Q1 2026, Equity Ratio changed N/A year-over-year to 0.44; the trailing twelve-month figure through Mar 2026 stood at 0.44 (changed N/A YoY), and the FY2025 full-year result was 0.0, down 101.11% from the prior year.
- Equity Ratio for Q1 2026 stood at 0.44, up from 0.0 in the prior quarter.
- The five-year high for Equity Ratio was 0.44 in Q1 2026, with the low at 0.0 in Q4 2025.
- Historically, Equity Ratio has averaged 0.29 across 3 years, with a median of 0.42 in 2024.
- The largest YoY upside for Equity Ratio was 101.11% in 2025 against a maximum downside of 101.11% in 2025.
- 20's Equity Ratio stood at 0.42 in 2024, then plunged by 101.11% to 0.0 in 2025, then soared by 9566.94% to 0.44 in 2026.
- The last three Equity Ratio figures came in at 0.44 (Q1 2026), 0.0 (Q4 2025), and 0.42 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 0.47 |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 0.50 |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 0.54 |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 0.59 |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 0.78 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.42 |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 0.45 |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 0.29 |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 0.67 |
| 10 | 20 | - | - | 62,884.00 | 0.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.44 |
| Dec 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.42 |